Table S2 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Santosh Gupta,Susan Halabi,Qian Yang,Akash Roy,Alisa Tubbs, Yamini Gore,Daniel J. George,David M. Nanus,Emmanuel S. Antonarakis,Daniel C. Danila,Russell Z. Szmulewitz,Richard Wenstrup,Andrew J. Armstrong

crossref（2023）

引用 0|浏览0

暂无评分

摘要

The prevalence of PSMA and Cell Search CTC positivity (≥5) at baseline and progression, as well as the observed median and optimal cutoffs for PSMA CTC.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要